A DNA Hypomethylation Signature Predicts Antitumor Activity of LSD1 Inhibitors in SCLC

Helai P. Mohammad(Arysta LifeScience (France)), Ryan G. Kruger(Arysta LifeScience (France)), Jeffrey D. Carson(GlaxoSmithKline (United States)), Charles F. McHugh(GlaxoSmithKline (United States)), Meagan B. Rouse(GlaxoSmithKline (United States)), N.O. Concha(GlaxoSmithKline (United States)), Yuchen Bai(The University of Melbourne), Michelle Crouthamel(AbbVie (United States)), Dashyant Dhanak(Wilmington University), Michael T. McCabe(GlaxoSmithKline (United States)), Michael Butticello(GlaxoSmithKline (United States)), Chandrashekhar D. Kamat(Johns Hopkins University), Xinrong Tian(GlaxoSmithKline (United Kingdom)), Yan Degenhardt(Cancer Research Institute), Christine L. Hann(Johns Hopkins University), Melissa B. Pappalardi(GlaxoSmithKline (United States)), Kenneth C. McNulty(GlaxoSmithKline (United States)), Thau Ho(GlaxoSmithKline (United States)), David Soong(GlaxoSmithKline (United States)), Peter J. Tummino(Intarcia Therapeutics (United States)), Jiri Kasparec(GlaxoSmithKline (United States)), Jess Schneck(GlaxoSmithKline (United States)), Shelby Gorman(GlaxoSmithKline (United States)), Kimberly N. Smitheman(GlaxoSmithKline (United States)), Glenn S. Van Aller(GlaxoSmithKline (United Kingdom)), Kelly Federowicz(GlaxoSmithKline (United States)), Neil W. Johnson(Brandywine Photonics (United States)), Yan Liu(Qingdao University), William H. Miller(Clinical Innovations (United States)), Christopher L. Carpenter(GlaxoSmithKline (United States)), Timothy K. Hart(GlaxoSmithKline (United States)), William G. Bonnette(GlaxoSmithKline (United States)), Patrick McDevitt(GlaxoSmithKline (United States))
Cancer Cell
July 1, 2015
Cited by 518


Related Papers